A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility.

Published on Aug 11, 2021in Annals of Oncology18.274
· DOI :10.1016/J.ANNONC.2021.08.1746
I.M. Modlin (Yale University), M. Kidd + 8 AuthorsLisa Bodei25
Estimated H-index: 25
(MSK: Memorial Sloan Kettering Cancer Center)
Sources
Abstract
Background null Biomarkers are key tools in cancer management. In neuroendocrine tumors (NETs), Chromogranin A (CgA) was considered acceptable as a biomarker. We compared the clinical efficacy of a multigenomic blood biomarker (NETest) to CgA over a 5-year period. null null null Patients and methods null An observational, prospective, cross-sectional, multicenter, multinational, comparative cohort assessment. Cohort 1: NETest evaluation in NETs (n = 1684) and cancers, benign diseases, controls (n = 731). Cohort 2: (n = 1270): matched analysis of NETest/CgA in a sub-cohort of NETs (n = 922) versus other diseases and controls (n = 348). Disease status was assessed by response evaluation criteria in solid tumors (RECIST). NETest measurement: qPCR [upper limit of normal (ULN: 20)], CgA (EuroDiagnostica, ULN: 108 ng/ml). Statistics: Mann-Whitney U-test, AUROC, chi-square and McNemar' test. null null null Results null Cohort 1: NETest diagnostic accuracy was 91% (P null 94% versus CgA 11%. null null null Conclusion null NETest accurately diagnoses NETs and is an effective surrogate marker for imaging, grade, metastases and disease status compared to CgA. A multigenomic liquid biopsy is an accurate biomarker of NET disease.
📖 Papers frequently viewed together
29 Citations
5 Authors (Irvin M. Modlin, ..., Lisa Bodei)
9 Citations
References26
Newest
Neuroendocrine neoplasms are derived from the diffuse endocrine system and represent a spectrum of tumours with a diverse range of molecular abnormalities, functionality and anatomical locations. Here, some key advances in molecular diagnosis, functional imaging and therapeutic strategies that have been published in 2020 are discussed.
6 CitationsSource
#2Dennis van der ZeeH-Index: 2
Last. Gerlof D. ValkH-Index: 40
view all 11 authors...
Reliable prediction of disease status is a major challenge in managing gastroenteropancreatic neuroendocrine tumors (GEP-NET). The aim of the study was to validate the NETest®, a blood molecular genomic analysis, for predicting the course of disease in individual patients compared to Chromogranin A (CgA). NETest® (normal ≤20%) and CgA (normal 140ng/ml), NPV and PPV were 83% and 52%. CgA could not predict PD in watchful waiting or NED subgroups. The NETest® reliably predicted SD and was the stron...
6 CitationsSource
#1Mark KiddH-Index: 5
#2Alexandra KitzH-Index: 2
Last. Irvin M Modlin (Yale University)H-Index: 3
view all 4 authors...
BACKGROUND: The NETest is a multi-gene assay comprising 51 circulating neuroendocrine tumor specific transcripts. The quotient of the 51-gene assay is based upon an ensemble of machine learning algorithms. Eight cancer hallmarks or "omes" (apoptome, epigenome, growth factor signalome, metabolome, proliferome, plurome, secretome SSTRome) represent 29 genes. The NETest is an accurate diagnostic (>90%) but its prognostic utility has not been assessed. In this study, we describe expansion of the NET...
5 CitationsSource
#1Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
#2Heiko Schöder (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 77
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 8 authors...
Peptide receptor radionuclide therapy (PRRT) is a type of radiotherapy that targets peptide receptors and is typically used for neuroendocrine tumours (NETs). Some of the key challenges in its use are the prediction of efficacy and toxicity, patient selection, and response optimisation. In this Review, we assess current knowledge on the molecular profile of NETs and the strategies and tools used to predict, monitor, and assess the toxicity of PRRT. The few mutations in tumour genes that can be e...
17 CitationsSource
#1Anna MalczewskaH-Index: 12
Last. Beata Kos-KudłaH-Index: 31
view all 16 authors...
BACKGROUND: There is a substantial unmet clinical need for an accurate and effective blood biomarker for neuroendocrine neoplasms (NEN). We therefore evaluated, under real-world conditions, the clinical utility of the NETest as a liquid biopsy in an ENETS Centre of Excellence and compared its utility with chromogranin A (CgA). Methods Cohorts: Gastroenteropancreatic (GEP)-NEN (n=253), bronchopulmonary (BP)-NEN (n=64), thymic NEN (n=1), colon cancer (n=37), NSCLC (n=63), benign lung disease (n=59...
9 CitationsSource
#1Marianne PavelH-Index: 52
#2Kjell Öberg (Uppsala University)H-Index: 116
Last. Alfredo Berruti (University of Brescia)H-Index: 66
view all 7 authors...
99 CitationsSource
#1Kjell ÖbergH-Index: 116
#2Andrea Califano (Columbia University)H-Index: 76
Last. S. Paulson (Baylor University)H-Index: 1
view all 11 authors...
Background The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease has hindered management. The advance of genomic medicine and the development of molecular biomarkers has provided a strategy—liquid biopsy—to facilitate real-time management. We reviewed the role of a blood mRNA-based NET biomarker, the NETest, as an in vitro diagnostic (IVD). Patients and methods A systematic review of the literature using the Preferred Reporting Items for Systematic Reviews and Meta-Analys...
29 CitationsSource
#1Angela LamarcaH-Index: 19
#2Hamish CloustonH-Index: 1
Last. Juan W ValleH-Index: 61
view all 10 authors...
The incidence of neuroendocrine neoplasms (NENs) is increasing, especially for patients with early stages and grade 1 tumours. Current evidence also shows increased prevalence, probably reflecting earlier stage diagnosis and improvement of treatment options. Definition of adequate postsurgical follow-up for NENs is a current challenge. There are limited guidelines, and heterogeneity in adherence to those available is notable. Unfortunately, the population of patients at greatest risk of recurren...
8 CitationsSource
#1Eric LiuH-Index: 1
#2Scott Paulson (Texas Oncology)H-Index: 1
Last. Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
view all 9 authors...
BACKGROUND: The clinical relevance of molecular biomarkers in oncology management has been recognized in breast and lung cancers. We evaluated a blood-based multigene assay for management of neuroendocrine tumors (NETs) in a real-world study (U.S. registry NCT02270567). Diagnostic accuracy and relationship to clinical disease status in two cohorts (treated and watch-and-wait) were evaluated. MATERIALS AND METHODS: Patients with NETs (n = 100) were followed for 6-12 months. Patients' primary tumo...
25 CitationsSource
#1Anna Malczewska (Medical University of Silesia)H-Index: 12
#2Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 4 authors...
Context: Early cancer detection is critical to optimize treatment. This is particularly problematic in neuroendocrine tumors (NETs), which exhibit an ∼5-year diagnostic delay due to covert symptoms, limitations in imaging, and circulating biomarkers. Despite development of continuous monitoring strategies utilizing advanced modalities [CT/MRI or 68Gallium positron emission tomography (PET)/CT] or a repertoire of monoanalyte biomarkers [e.g., chromogranin A (CgA), pancreastatin, serotonin], detec...
18 CitationsSource
Cited By0
Newest